Genotype imputation estimates unobserved genotypes from genome-wide makers, to increase genome coverage and power for genome-wide association studies. Imputation has been successful for European ancestry populations in which very large reference panels are available. Smaller subsets of African descent populations are available in 1000 Genomes (1000G), the Consortium on Asthma among African ancestry Populations in the Americas (CAAPA) and the Haplotype Reference Consortium (HRC). We compared the performance of these reference panels when imputing variation in 3747 African Americans (AA) from two cohorts (HCV and COPDGene) genotyped using Illumina Omni microarrays. The haplotypes of 2504 (1000G), 883 (CAAPA) and 32,470 individuals (HRC) were used as reference. We compared the number of variants, imputation quality, imputation accuracy and coverage between panels. In both cohorts, 1000G imputed 1.5-1.6× more variants than CAAPA and 1.2× more than HRC. Similar findings were observed for variants with imputation R 2 > 0.5 and for rare, low-frequency, and common variants. When merging imputed variants of the three panels, the total number was 62-63 M with 20 M overlapping variants imputed by all three panels, and a range of 5-15 M variants imputed exclusively with one of them. For overlapping variants, imputation quality was highest for HRC, followed by 1000G, then CAAPA, and improved as the minor allele frequency increased. 1000G, HRC and CAAPA provided high performance and accuracy for imputation of African American individuals, increasing the number of variants available for subsequent analyses. These panels are complementary and would benefit from the development of an integrated African reference panel.
Introduction
Over the past 10 years, genome-wide association studies (GWAS) have uncovered a large number of replicated associations for many complex human diseases (Marchini and Howie 2010; McRae 2017; Visscher et al. 2017) . These studies have used different genotyping arrays with 300,000 to 2.5 million single nucleotide polymorphisms (SNPs), varied genomic coverage, and a wide range of allelic frequencies across populations. In general, these arrays provide excellent genomic coverage and density for European ancestry populations. Despite efforts at enrichment, imputation remains modest at best for other ancestral populations, especially populations of African ancestry. Genotype imputation is a cost-effective method for statistically predicting untyped genotypes not directly assayed in a sample of individuals based on a dense reference panel of haplotypes. Imputation methods estimate haplotypes of observed genotypes shared between genotyped individuals and a sequenced reference panel, and use this information to infer alleles at untyped SNPs (Marchini and Howie 2010) . This process can increase the overall genome coverage of an array by increasing the number of testable single nucleotide variants (SNVs) across the entire genome and can improve fine mapping of a targeted region of interest. Imputation also facilitates the comparison and meta-analyses of studies originally done on different arrays (Marchini and Howie 2010; Hancock et al. 2012; Das et al. 2016; McRae 2017) , potentially bridging the gap in coverage between various genome-wide SNP platforms (Anderson et al. 2008 ).
Imputation of rare SNVs is more challenging since rare alleles are often ethnicity or population specific and reflect fine-scale linkage disequilibrium (LD) structure impacted by recent demographic events (Wojcik et al. 2017) . Options for imputing low-frequency and rare variants more accurately in any specific population include increasing the size of the imputation reference panel to capture more reference haplotypes, or increasing the sequencing depth in the reference samples to minimize error rates inherent in low-coverage sequencing (Browning and Browning 2009 ). Recently admixed populations, which have higher degrees of LD and greater heterogeneity in their haplotype block structure (reflecting the dynamics of admixture), may also benefit from using more diverse or larger reference populations.
Earlier available reference panels include the Human Genome Diversity Project (Cavalli-Sforza 2005) , the HapMap Consortium (The International HapMap 3 Consortium et al. 2010 ) and the 1000 Genomes Project (1000G) (Sudmant et al. 2015) . More recently, the Haplotype Reference Consortium (HRC) (McCarthy et al. 2016 ) was constructed via a predominantly European ancestry consortium currently comprising 32,611 individuals with whole-genome or exome sequences available. The HRC includes the Genome of The Netherlands (GoNL), 250 Dutch parent-offspring families sequenced at 12× depth (Genome of the Netherlands Consortium et al. 2014) , the UK10K project with nearly 10,000 individuals whose whole genome was sequenced at 7×, or exome sequenced at 80× (Walter et al. 2015) and 1000G subjects among other cohorts (http://www.haplo type-refer ence-conso rtium .org/parti cipat ing-cohor ts). Another project, funded by the UK government, plans to sequence 100,000 whole genomes from patients registered and treated by the National Health Service (http://www.genom icsen gland .co. uk/the-10000 0-genom es-proje ct/). These dense reference panels will allow better imputation of low-frequency and rare variants (Deelen et al. 2014 ) and the discovery of new variants (Walter et al. 2015; Warren et al. 2017) , but are generally focused on populations of European descent.
There are a only few reference panels available for imputation in African Americans and include 1000G (Sudmant et al. 2015) and the Consortium on Asthma among African ancestry Populations in the Americas (CAAPA) (Mathias et al. 2016) . The 1000G includes 661 individuals with African ancestry from Esan, Gambian, Luhya, Mende, Yoruba, Barbadian, and African American populations (Sudmant et al. 2015) . The CAAPA panel is an additional resource completed on populations of African ancestry from the Americas (Mathias et al. 2016) . CAAPA included 883 unrelated individuals of African descent from 15 locations in North, Central, and South America, the Caribbean, and Yoruba-speaking individuals from Nigeria. The relatively small size of these panels compared to the reference populations for European ancestry limits the ability to discover new variants beyond those already present on the commercially available chips for subjects of African descent. Other projects assessing genetic diversity through dense genotyping and at the whole genome sequence (WGS) level in African populations include the African Genome Variation Project (AGVP) (Gurdasani et al. 2014 ) and the African Genome Resources (AGR) reference panel (https ://www.apcdr .org/).
In this paper, we compared imputation performance using publicly available reference panels to evaluate imputation accuracy and quality in African or admixed populations of African descent. Imputation performance has been evaluated for African American populations comparing 1000G, HapMap, and the Exome Sequencing Project (Chanda et al. 2012; Hancock et al. 2012; Sung et al. 2012; Duan et al. 2013; Roshyara et al. 2016) , and also using several combinations of populations from 1000G. Previous analyses suggest multi-ethnic panels in 1000G (primarily European (EUR) and African (AFR)) improve imputation performance compared to a reference panel from any single population (AFR) (Chanda et al. 2012) . In previous studies of African Americans imputed with several combinations of 1000G populations, imputation accuracy (based on concordance and imputation quality score) was comparable across the reference panels. Imputation quality for SNPs with MAF between 0.02 and 0.50 was better when using more distantly related reference panels containing several continental African populations (AFR + EUR or ALL populations) in comparison with more closely related populations [Yoruba (YRI), CEPH European (CEU) and African Americans from the Southwest USA (ASW)], but when analyzing all ranges of MAF including those with MAF < 0.02, the most closely related (YRI + CEU + ASW) panel produced better imputation results. On the other hand, genotype concordance was similar for both distant and closely related reference panels from 1000G (Hancock et al. 2012) .
Imputation is a standard part of all array-based genomewide association analyses. However, the relative performance of these newer imputation reference panels-with varying total sample size and number of African individuals-is unknown. In this study, we extend these prior imputation comparisons beyond the 1000G populations by evaluating genotype imputation performance using CAAPA, HRC, and 1000G reference panels in two independent populations of African Americans (Regan et al. 2010; Duggal et al. 2013; Wojcik et al. 2014 ).
Methods
The current study includes a total of 3747 African Americans participating in previous genome-wide association studies of spontaneous resolution of hepatitis C viral infection (HCV cohort) and chronic obstructive pulmonary disease (COPD) from the COPDGene cohort, a multi-site study of heavy smokers (Regan et al. 2010; Duggal et al. 2013; Wojcik et al. 2014) . The metrics of imputation performance, accuracy, genome coverage, and annotation of variants were calculated in these two cohorts separately.
Study subjects

African Americans from the HCV cohort
A genome-wide marker panel from 447 African Americans was used, as previously described (Duggal et al. 2013; Wojcik et al. 2014) . Briefly, 2401 individuals participating in a longitudinal cohort study or identified through blood repositories as having HCV infection (spontaneously resolved or persistent) were enrolled and were genotyped as part of the HCV Genetics Consortium. African American subjects are part of a multicenter cohort composed of several study groups including ALIVE (AIDS Link to the Intravenous Experience, Baltimore, MD) (Vlahov et al. 1990 ); BBAASH (Baltimore Before and After Acute Study of Hepatitis, Baltimore, MD) (Cox et al. 2005) ; BAHSTION (Boston Acute HCV Study: Transmission, Immunity and Outcomes Network, Boston, MA) (Kim et al. 2011 ); Cramp and colleagues' study at King's College Hospital, London, UK (Cramp et al. 1998) ; HGDS (Hemophilia Growth and Development Study in 14 hemophilia treatment centers in USA) (Hilgartner et al. 1993 ); Mangia and colleagues' study at San Giovanni Rotondo, Italy (Mangia et al. 1999) ; MHCS (Multicenter Hemophilia Cohort Study) and MHCS-II recruited in 16 sites located in the USA, Greece, Germany, and Austria (Goedert et al. 2007 ); REVELL study (Correlates of Resolved vs. Low-Level Viremic Hepatitis C Infection in Blood Donors recruited at 17 blood banks in Western and Southern USA) (Tobler et al. 2010) ; the Swan Project recruited at the Lower East Side of Manhattan, NY (Edlin et al. 2009 ); the Toulouse cohort form the south of France (Alric et al. 1997) ; WIHS (Women's Interagency HIV Study), a multicenter study with ten recruitment sites across the USA (Kuniholm et al. 2011) ; and the United Kingdom Drug Use cohort, London, UK (Khakoo et al. 2004) . Each individual study obtained consent for genetic testing from their governing Institutional Review Board (IRB) and the Johns Hopkins School of Medicine Institutional Review Board.
African Americans from the COPDGene cohort
This study included 3300 African American participants in the COPDGene study. A complete study protocol for COPDGene had been described elsewhere (Regan et al. 2010) . Briefly, 10,280 self-identified non-Hispanic Whites and African Americans between the ages of 45 and 80 years with a minimum of 10 pack-years smoking history were enrolled at 21 centers across the USA with the goal of identifying genetic causes of COPD. The majority were recruited from: Temple University, Philadelphia, PA (n = 798), Morehouse School of Medicine, Atlanta, GA (n = 454), Harbor-UCLA Hospital, Los Angeles, CA (n = 368), University of California San Diego, San Diego, CA (n = 319), Columbia University, New York, NY (n = 309), and Johns Hopkins University, Baltimore, MD (n = 251). Each study site obtained local IRB approval to enroll participants in this project, and all subjects provided informed consent (Regan et al. 2010) .
Genotyping and quality control
African Americans from the HCV cohort Genetic variants and their locations for the genotypic data, reference panels, and WGS data were specified based on the Genome Reference Consortium Human build 37 (GRCh37) (Lander et al. 2001) . A total of 774,792 SNPs genotyped on the Illumina Omni Quad array (Illumina, Inc. San Diego) met quality control criteria and were used for imputation. SNPs with MAF < 0.01, those with missing call rate ≥ 5% and those deviating from Hardy-Weinberg equilibrium at P < 1 × 10 −5 were removed from the analysis for quality control. Individuals cryptically related, duplicated replicates, and individuals with sex discrepancies were excluded (Duggal et al. 2013) .
African Americans from the COPDGene cohort
A total of 624,564 SNPs genotyped on the Illumina Omni Express array (Illumina Inc. San Diego, CA) were used for imputation. All SNPs with MAF < 0.05, those with missing call rate ≥ 2%, those deviating from Hardy-Weinberg equilibrium at P < 1 × 10 −3 and individuals cryptically related, duplicated replicates, and individuals with sex discrepancies were excluded (Cho et al. 2012 ).
Whole-genome sequencing: library preparation and bioinformatic analysis
Whole-genome sequencing data in a subgroup of 17 subjects of the HCV cohort was performed at the New York Genome Center. In brief, libraries of 350-bp fragments were generated from 1 µg sheared genomic DNA using the TruSeq PCR-Free library preparation kit (Illumina, San Diego, CA). WGS was performed at a coverage of 30×. Base calling and filtering were performed using current Illumina software; sequences were aligned to NCBI genome (build 37) using Burrows-Wheeler Aligner (Li and Durbin 2009 ); Picard was used to remove duplicate reads (http://broad insti tute. githu b.io/picar d/); base quality scores were recalibrated using GATK (DePristo et al. 2011) . Assessment of reads not aligning fully to the reference genome was performed, locally realigning around indels to identify putative insertions or deletions in the region. Variants were called using GATK HaplotypeCaller tool, which generates single-sample Genomic VCF (GVCF) files. To improve variant call accuracy, multiple single-sample GVCF files were jointly genotyped using GATK Genotype GVCFs, which generates a multi-sample VCF. Variant quality score recalibration (VQSR) was performed on the multi-sample VCF, which adds quality metrics to each variant that can be used in downstream variant filtering (Van der Auwera et al. 2013) . Quality control of all variants included filtering out based on genotyping quality score < 20, read depth < 10, and removing variants in genomic duplicated segments.
Estimation of genetic African American ancestry
The genetic ancestry for both cohorts was determined by principal components using the smartpca program in EIGENSOFT (Price et al. 2006) . A subset of independent SNPs across the genome were selected by pruning the full dataset for markers with an R 2 < 0.01 to insure independence between SNPs. Chromosomal regions known to be associated with ethnicity were removed (including the lactase regions on chromosomes 2, 8, and the HLA region on chromosome 6). African American ancestry groups were determined based on their distribution over the first two principal components ( Supplementary Fig. 1 ). Outliers were removed based on heterozygosity, and if the subjects were 6 standard deviations from either of the two first principal components (Regan et al. 2010; Duggal et al. 2013) . We also performed local ancestry inference on both the HCV and COPDGene cohorts using the algorithm implemented in the Local Ancestry in adMixed Populations (LAMPLD) software (Baran et al. 2012; Parker et al. 2014; Wojcik et al. 2014) . Averaging local ancestry estimates over all sites, COPDGene and HCV subjects have an average of 80.7 and 79.5% African ancestry, respectively, with a range of 29.5-99.6% African ancestry in both cohorts.
Phasing and imputation
For both cohorts, Eagle v2.3, a reference-based phasing algorithm, was used to phase genotypes prior to imputation (Durbin 2014; Loh et al. 2016) . Imputation was performed for chromosomes 1-22 using the Minimac3 software through the publicly available Michigan Imputation Server . Minimac3 is a Markov chain-based haplotyper that can resolve long haplotypes or infer missing genotypes in samples of unrelated individuals (Li et al. 2010) . Imputation of genotypes was performed using three different reference panels:
1. 1000 genomes phase 3, version 5 (referred to here as "1000G") included 49,143,605 sites located in chromosomes 1-22 for the complete set of 2504 individuals representing five continental and sub-continental populations: East Asian (EAS = 504), European (EUR = 503), South Asian (SAS = 489), African (AFR = 661), and mixed American (AMR = 347) (Sudmant et al. 2015 
Imputation performance metrics
Evaluation of imputed variants by reference panel
For each reference panel and cohort, we assessed imputation performance using the following criteria: (1) the total number of imputed variants; (2) the distribution of all variants based on MAF ranges; and (3) the relationship between imputation quality and MAF. Imputation quality was determined using the R 2 score, or the estimated value of the squared correlation between imputed genotypes and true, unobserved genotypes basing its calculation on the population allelic frequencies (Howie et al. 2012 ).
Comparison of imputed variants between reference panels
To compare imputation results between panels, we analyzed variants imputed by all three panels ("overlapping" variants) and exclusively by each panel ("unique" variants) . For overlapping variants, the imputation quality and genotype concordance between the panels was compared. Unique variants with R 2 > 0.5, were evaluated by their number and MAF and for its presence and MAF in the CEU, YRI, and CHB populations from1000G as a method to evaluate their potential ancestral origin.
Imputation accuracy
Imputation accuracy is defined as the proportion of correctly imputed SNPs among all successfully imputed SNPs (Zhao et al. 2008; Huang et al. 2009; Nothnagel et al. 2009; Zhang et al. 2011) . We calculated imputation accuracy using three separate approaches:
1. A "masked analysis" where we removed genotypes of a subset of 25,000 SNPs and then imputed them as though they were not genotyped. Imputed genotypes of these SNPs then were compared back to their original genotypes (Huang et al. 2009; Shriner et al. 2010; Hancock et al. 2012) . The MAF of these SNPs ranged from 0.01 to 0.5; 2. A comparison of the allelic dosage of the original genotypic data with the allelic dosage of imputed data. Given three genotypes AA, AB, and BB for each SNP, the allelic dosage for each individual can be calculated as probabilities (P) of each of three genotypes via 2 × P (AA) + 1 × P(AB) + 0 × P(BB) to obtain the expected allelic dosage from the original genotypic data and from the observed allelic dosage for masked and imputed genotype at each SNP (Verma et al. 2014) . The metric EmpRsq obtained in Minimac3 is the correlation between the true genotyped values and the imputed dosages calculated by hiding all known genotypes for a given SNP (Howie et al. 2012 ), similar to the masked analysis described above. We calculated the mean of this EmpRsq by bins of 0.001-0.01 value of frequency of the minor allele. 3. A comparison of the imputed genotypes with wholegenome sequencing genotypes in a subgroup of 17 individuals from the HCV study. This analysis was restricted to variants located on chromosome 22 and was done independently for all the variants imputed with each reference panel.
Genomic coverage and density of imputed variants
The total proportion of genomic variation captured by an array, either directly or indirectly, is referred to as "genomic coverage". Assessments of imputation-based genomic coverage leverages observed array SNPs which imputed from a more densely genotyped or sequenced reference panel, such as the HapMap Project3 or 1000 Genomes Project (Abecasis et al. 2012; Auton et al. 2015) . In this study we based our calculations on the imputation R 2 (calculated as squared correlation between the actual (discrete) allelic dosage at an SNP and the imputed (continuous) allelic dosage, over a defined set of samples). Genomic coverage was quantified as the proportion of variants with an imputation R 2 ≥ 0.8, and the reference set of variants used to determine imputationbased genomic coverage was the total number of variants described in each imputation reference panel. This method has been described and used previously as one assessment of genomic coverage in imputation performance studies (Hoffmann et al. 2011; Nelson et al. 2013) .
We also calculated the density of imputed variants (represented as the number of variants with R 2 > 0.8 per kb) across all autosomes, by chromosomes and in chromosomal regions harboring known genes. We compared the results obtained with the three panels. Variants genotyped on the arrays were given imputation R 2 = 1 for all coverage and density calculations; chromosome sizes in base pairs were obtained from the UCSC Known Gene Human Annotation (GRCh37). Coordinates of the regions containing genes were obtained from the RefSeq database via UCSC genome browser (Kent et al. 2002) (http://genom e.ucsc.edu/). Plink version 1.90 beta (Purcell et al. 2007 ), bcftools (Danecek et al. 2011 ) and customized scripts in R (R Core Team 2013) were used for the analyses with both cohorts.
Results
Imputation performance metrics
Evaluation of imputed variants by reference panel
The total number of imputed variants and their distribution by MAF was similar for both the HCV and COPDGene cohorts (Table 1 and Supplementary Table 1) . In both cohorts, 1000G imputed approximately 1.5× more variants than did CAAPA, and 1.2× more variants than did HRC regardless of imputation quality. However, it is important to note the 1000G imputation includes small insertions/deletions (INDELS) that are not currently available in the HRC and CAAPA panels. These INDELS corresponded approximately 7.0% of total imputed variants in both cohorts. The actual values of this and other metrics obtained in the 1 3
COPDGene cohort are described in detail in Supplementary Results.
For variants imputed with R 2 > 0.5, 1000G imputed nearly 1.4× and 1.3× more variants in both cohorts. In the HCV cohort they were 26,310,578 vs. 18,584,433 and 20,643,333 for CAAPA and HRC, respectively. All three reference panels had a similar percent of variants imputed with R 2 > 0.5 in both cohorts being slightly high for the COPDGene cohort. For the HCV cohort, HRC had 53%, 1000G 56%, and CAAPA 62%. For the three panels, the percentage of variants imputed with R 2 > 0.5 increased with increasing MAF (Table 1 and Supplementary Table 1) .
Regardless of allele frequencies, the number of imputed variants was greater in 1000G than for CAAPA: ~ 1.8× more rare variants (MAF = 0.0001-0.01), ~ 1.3× more low MAF variants (MAF = 0.01-0.05) and ~ 1.2× more common variants (MAF > 0.05). These numbers were also higher for 1000G compared to HRC being 1.4×, 1.1× and 1.2×, respectively. The distribution of the number of variants with R 2 > 0.5 by MAF for each panel was similar between all reference panels with a high number of low-frequency SNPs (i.e., those with MAF < 0.1) in the three panels.
For both cohorts and all three panels, imputation quality improved as the MAF increased, reaching a mean quality score or R 2 of 0.6 or higher for common variants (MAF > 0.05). CAAPA imputed with slightly lower quality across all MAF followed by 1000G and HRC ( Fig. 1 and Supplementary Fig. 2 ). The higher imputation quality observed with HRC and 1000G was particularly evident in low-frequency variants (i.e., those with MAF from 0.002 to 0.05). In the COPDGene cohort, HRC had a better performance compared to 1000G for very rare variants (MAF < 0.001, Supplementary Fig. 2 ), but this was not observed in the HCV cohort, likely due to sample size differences in the two target populations.
Comparison of imputed variants between reference panels
When merging the variants imputed independently with each reference panel, the total number of imputed variants was 62-63 million, representing an increase of 20-30 million variants compared to the imputation of each panel separately (Fig. 2, Supplementary Fig. 3 and Supplementary Table 2 ). There were approximately 20 million overlapping variants imputed with all three reference panels and a range of 5-15 million unique variants imputed exclusively within one of the three panels.
For overlapping variants, we compared the imputation quality obtained with each of the three panels ( Fig. 3 and Supplementary Fig. 4 ). For the same variants, the imputation quality was higher for HRC and 1000G compared to imputation run against CAAPA. From approximately 20 million overlapping variants, HRC and 1000G imputed ~ 18-19 million variants with R 2 > 0.5, whereas CAAPA imputed ~ 15 million ( Fig. 3 and Supplementary Fig. 4 ). Genotype calls of overlapping variants were 98-99% concordant between pairs of panels in both cohorts.
Unique variants corresponded to 17, 31, and 27% of all variants imputed with CAAPA, 1000G, and HRC, respectively. Most of them had MAF < 0.01 (75-90%) in both cohorts for the three panels (Supplementary Tables 3 and 4) , and 5-24% of these rare variants were imputed with R 2 > 0.5. There was a lower percentage (0.2-5%) of low-frequency variants (MAF between 0.01 and 0.05) that were imputed with better quality (> 45% had R 2 > 0.5). The percentage of all unique variants imputed with R 2 > 0.5 in the HCV cohorts was 27% for 1000G, 24% for CAAPA, and 4% for HRC and slightly higher percentages were observed for the COPDGene cohort (Supplementary Results).
We interrogated the three parental populations of 1000G (CEU, YRI, and CHB) to estimate allele frequencies of unique variants imputed with R 2 > 0.5 in each population. 31% of the variants imputed with CAAPA were present in parental populations of 1000G. Only a small percentage of those were polymorphic in the CEU and CHB (0.3-6% in both cohorts) as compared to YRI (12-22%), Supplementary Fig. 5 . Of those unique variants imputed using HRC, 34-35% were present in the parental populations; from those, 17-18% were polymorphic in CEU, in contrast with a 0.5-4 and 2% of variants that were polymorphic in YRI and CHB in both the HCV and COPDGene cohorts. All the unique variants with R 2 > 0.5 imputed with 1000G in both cohort were also present in the parental populations, and 30-60% were actually polymorphic (i.e., MAF > 0) in YRI, CEU, and CHB (Supplementary Results).
Imputation accuracy
The concordance of genotype calls between the original genotype data and imputed data was quite high (96-97%) across all three panels using masked SNPs from both cohorts. The correlations between dosages of the imputed genotypes and actual genotypes ranged from 0.80 to 0.94, with higher correlations occurring when the MAF was greater than 1% ( Supplementary Fig. 6 ). In addition, we evaluated the concordance between WGS and imputed data using variants on chromosome 22 in the HCV cohort. The genotype concordance for the three panels was 99% for 213,467, 190,005, and 195,591 variants overlapping between sequenced genotypes and imputed genotypes with 1000G, CAAPA, and HRC, respectively.
Genomic coverage and density of imputed variants
In the HCV cohort, we imputed 20,222,182 variants with R 2 > 0.8 using the 1000G panel, 11,684,700 with CAAPA, and 16,941,215 with HRC. The genomic coverage was 0.41, 0.37, and 0.43 for 1000G, CAAPA, and HRC, respectively. Genomic density of markers included in the genotype array was estimated to be 0.3 marker/kb. In contrast, imputation with 1000G, CAAPA, and HRC increased the genome density to 7, 4.1, and 5.9 markers per kb, respectively. Similar values were observed in the COPDGene cohort (Supplementary Results). For both cohorts, the average density across chromosomes was ~ 6.8 variants/kb for 1000G, ~ 3.9 variants/kb for CAAPA, and ~ 5.7 variants/kb for HRC. The density was considerably lower in gene regions with an average ~ 1.4, ~ 2.3, and ~ 1.9 variants/kb for CAAPA, 1000G, and HRC, respectively (Supplementary Table 5 and 6).
Discussion
In the current study, we used three reference panels to impute GWAS genotyping data in two independent cohorts of African American individuals with remarkably consistent results between the two studies. Imputation to three reference panels increased coverage and density of markers across all autosomal chromosomes and facilitated the accurate imputation of both rare and common alleles with R 2 > 0.5. Somewhat surprisingly, despite the smaller size of the reference panel and number of African Americans, the 1000G reference panel resulted in a higher number of imputed variants (even after removing INDELS) than either the HRC or CAAPA cohorts alone. Additionally, while all three panels led to accurate estimated genotypes, the imputation quality was highest for HRC across all MAFs, but especially for low-frequency and rare variants.
A greater number of variants were imputed with 1000G as compared to CAAPA. The substantially larger sample size of the 1000G panel may explain this difference by itself. Previous studies comparing reference panels have shown that larger reference panels considerably increase the number of imputed variants, as well as their imputation quality and accuracy, particularly for low-frequency variants (Browning and Browning 2009; Deelen et al. 2014; McCarthy et al. 2016) . However, the composition of the reference population and similarity to the target population is also very important. Shriner et al. (2010) imputed variants on chromosome 22 in African Americans from the Washington, DC metropolitan area participating in the Howard University Family Study (Adeyemo et al. 2009 ) and concluded the YRI reference panel outperformed other HapMap reference panels, including ASW, as well as a combination of the CEU and YRI. Previous studies in European populations have indicated population-specific panels can improve imputation quality and coverage (Pistis et al. 2015; Mitt et al. 2017 ) compared to broader panels. This improvement in the number of variants imputed and the accuracy using population-specific panels argues that LD patterns of ethnic-specific variants may not be captured by different ethnic groups with distinct ancestral genetic background (Chou et al. 2016) , which might include haplotypes from irrelevant populations. We would expect a population-specific panel like CAAPA, genotyped at a high depth, where ~ 50% are African Americans with African ancestry estimates of 76% or higher (Mathias et al. 2016) , would be optimal for imputing more rare and common variants with higher quality in a target sample with similar high proportion of African ancestry (African ancestry estimates averaging 79.5%) (Duggal et al. 2013; Wojcik et al. 2014) . However, in our study, the higher number of individuals from populations from continental Africa contained in 1000G compared to CAAPA (N = 504 vs. N = 25) may have outweighed the larger number of total African ancestry individuals in CAAPA and provided more information on parental haplotype diversity (Jorde et al. 2000; Campbell and Tishkoff 2008) , improving the chances of a rare variant being effectively tagged by a characteristic haplotype in admixed individuals (Auton et al. 2015) .
1000G also imputed more variants than HRC in both cohorts. The difference is primarily because of the imputation of INDELs by 1000G, but even after accounting for this, there is still a smaller total number of variants in HRC (even though 1000G is contained within this larger reference panel). The predominantly European ancestry haplotypes of the HRC panel might impair the selection of optimal haplotypes for imputation of these populations with high proportion of African ancestry and consequently explain why there was a less of an increase in imputation success in them. Our sensitivity analysis investigating the potential ancestral origin of the unique variants indicated 1000G was able to impute variants of European and African origin compared to the HRC panel alone where the unique variants were present mostly in the CEU population of 1000G, indicating an exclusive European origin. This may also explain why HRC imputed more variants than obtained with the CAAPA reference panel alone, if the higher number of imputed variants obtained with HRC compared to CAAPA reflects underlying European haplotypes in admixed African Americans. It is reasonable to suggest that the inclusion of more European and African parental populations in the CAAPA panel will improve its performance.
Our results are remarkably consistent in the two datasets even though they were imputed based on two diverse genotyping platforms and have different sample sizes. Previous analysis have demonstrated that differences in the density and distribution of markers in diverse genotyping array play a role in the results of imputation (Marchini and Howie 2010; Nelson et al. 2017) ; however, our findings suggest that a difference in 150K genotyped markers in these two platforms does not alter the imputation performance. On the other hand, some studies indicate that merging the individual datasets before imputation performs slightly better than combining datasets after imputation (van Iperen et al. 2017) . Since the actual analysis was not done here, it is unknown if, for these two particular studies, the results of the imputation of the datasets separately are comparable to those potentially obtained with the imputation of the intersection of the two datasets, as required and recommended (Johnson et al. 2013) for analyzing combined datasets in association studies.
Regardless of the reference panel, imputation yielded accurate genotypes as shown in the analysis of correlation between true genotypes and imputed genotypes, the masked analysis and the concordance analysis comparing imputed SNPs and sequencing data in the HCV cohort. The accuracy reflected in the estimated correlation of true genotypes and imputed genotypes was comparable (but slightly higher) for 1000G when studied as a function of minor allele frequency. The lower accuracy found using the CAAPA and HRC reference panels separately might be due to the inclusion of admixed populations without a large African and European ancestral panel in CAAPA or the predominance of European haplotypes in HRC. This could limit selection of the best reference haplotypes. Imputation accuracy increases with the number of haplotypes in the reference panel of sequenced genomes (Howie et al. 2012; Fuchsberger et al. 2015; Pistis et al. 2015) , particularly for rare and low-frequency variants. The estimation of the effect of effective sample size (and ancestral composition) of a reference panel has been the subject of analysis of several papers for populations of diverse ancestry and demographic history (Chanda et al. 2012; Krithika et al. 2012; Duan et al. 2013; Huang and Tseng 2014; Huang et al. 2015) . Previous studies determined that reference panels as small as 60 European ancestry individuals were sufficient for imputation in a set of 2759 European Americans with imputation accuracy of 0.91 for variants with MAF > 5% using Minimac (Li et al. 2010) . Similarly for a MAF > 5%, 60 individuals of European ancestry and 59 of African ancestry (CEU/YRI of 1000G) were sufficient to obtain an accuracy of 0.83 in a sample of 8421 African Americans from the Women's Health Initiative (WHI) study (Howie et al. 2012) . The authors note that the accuracy improvement is directly related to the sample size of the panel for these common variants. Therefore, we believe that the expansion of the number of sequenced individuals from African ancestral populations will be necessary for more accurate imputation, especially for rare variants. Additional studies evaluating the effective number of sequence based haplotypes for admixed populations are necessary to determine target goals for these reference panels for less frequent and rare variants.
In this study, we used global concordance as a measure of imputation accuracy excluding variants with MAF < 0.01. Accuracy can be inflated when calculations of concordance rate include rare and low-frequency variants, due to chance concordance or chance agreement (Lin et al. 2010; Ramnarine et al. 2015) . Due to the baseline low allele frequency, there is a low probability of any rare allele being present in any imputed sample; therefore, when the major allele is assigned in imputation, this inference would be almost uniformly "correct" by chance alone. This inflation is increasingly problematic whenever studies are more interested in evaluating low-frequency and rare variants. Since our study did not include rare variants in the estimate, we consider our obtained values reliable. Our global estimates of accuracy were higher than previous results obtained in a group of 40 African Americans imputed with MACH using CEU, YRI, MEX, and JPT + CHB-HapMap populations. Accuracy values (measured as percentage of most likely genotypes agreeing with the original genotypes) of 88.8, 87.9 and 87.2 were found when masking 50, 70, and 100% of all high-quality SNPs (Roshyara and Scholz 2015) . The differences between this study and the current analysis are likely due to our larger sample size and type of reference population (Hapmap vs. 1000G, HRC, and CAAPA, separately).
Imputation resulted in a considerable number of rare and common variants unique to CAAPA, although they are present in the 1000G database. These variants are predominantly of African origin even though a great number are monomorphic in YRI subjects and possibly for this reason they were not imputed in the 1000G panel. It is likely these unique variants may be derived from African genomes not included in the 1000G, and may be unique to African descent populations in the Americas (where there is also a small percentage of Native American genes included). Similarly, the unique variants imputed with HRC may correspond to European derived polymorphisms not captured by the haplotype structure of the other reference panels.
In this study, the total number of imputed variants increased when merging imputed variants obtained from each reference panel individually. However, although all panels are publicly available for imputation on the server and 1000G and a subset of CAAPA raw sequencing data are publically available and in dbGap under request, respectively, we were not able to evaluate the imputation of a fully integrated reference panel given that the full HRC is not available for off-line imputation. Previously, integration of the 1000G and African Genome Variation Project panels markedly improved imputation accuracy across the entire allele frequency spectrum for populations poorly represented in the 1000G panel (Gurdasani et al. 2014 ). Similar results were found when merging the Estonian Biobank of the Estonian Genome Center, University of Tartu (EGCUT) and 1000G datasets (Mitt et al. 2017 ) and the GoNL and 1000G (Pistis et al. 2015) and when using a combined reference panel of 1092 subjects from 1000G and 3781 from UK10K Project for imputing rare variants in the Framingham Heart Study and the North Chinese Study (Chou et al. 2016) . We encourage the development of more publicly available combined reference panels, like HRC, for African ancestry populations. The African Genome Resources (AGR) data is a great example with data merged with 1000G and available via the Sanger Imputation Center. The AGR incorporates ~ 2000 Ugandan samples and ~ 100 samples each from Ethiopia, Egypt, Namibia, and South African populations. These joint panels should also include the NHLBI funded Trans-Omics for Precision Medicine (TOPMed) project (Brody et al. 2017) . The TOPMed panel includes over 60,000 WGS samples (125,568 haplotypes), sequenced to a mean depth of 30×. Unlike the HRC panel, TOPMed sample are ~ 50% non-white, including ~ 25% (or ~ 15,000 samples) of African ancestry. The African ancestry samples in the TOPMed reference include the COPDGene subjects presented in this manuscript. We expect this huge sample of both African and European ancestry individuals will result in improved overlap of haplotypes represented in the reference and our African Americans subjects. Therefore, we expect more variants of higher quality will be imputed using the TOPMed panel. Additionally, unlike the HRC and CAAPA panels, TOPMed imputation through the Michigan Imputation Server includes small INDELs, affording investigators the opportunity to analyze these in addition to single nucleotide variants.
In addition, The 1000 Genomes Project will soon become "The International Genome Sample Resource" with all sequenced reads being re-mapped to the GRCh38 map producing new variants calls specific to this assembly. It will also expand the global catalog of freely available sequence information by incorporating Russian samples, new African populations, and whole-genome sequences from the Simons Genome Diversity Project (Zheng-Bradley and Flicek 2016). Data from the CAAPA project are also available at the database of Genotypes and Phenotypes (dbGaP) and can be used to explore the option of "custom reference panels" for imputation in African Americans and other admixed populations from Latin America and the Caribbean. But as we show in this study, there is still a need for characterizing large, diverse parental populations such as those from subSaharan Africa to better capture populations such as those in the Americas.
In summary, we found that the 1000G, HRC, and CAAPA reference panels provide high performance and accuracy for imputing dense marker panels for admixed African American individuals, increasing the total number of high-quality imputed variants available for subsequent analyses. The 1000G panel also showed higher performance compared to the HRC and CAAPA reference populations in terms of the number of imputed variants with high accuracy, likely because it included more diverse parental populations. Finally, there are a large number of variants unique to these three reference panels, making them complementary to each other. We recommend directing efforts to the construction of an integrated African panel including data from multiple resources and populations.
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